Virtu Financial LLC bought a new position in Guardant Health Inc (NASDAQ:GH) during the third quarter, Holdings Channel.com reports. The fund bought 10,156 shares of the company’s stock, valued at approximately $648,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in GH. FMR LLC raised its holdings in shares of Guardant Health by 28.3% in the 1st quarter. FMR LLC now owns 464,612 shares of the company’s stock worth $35,636,000 after purchasing an additional 102,483 shares in the last quarter. First Trust Advisors LP increased its position in shares of Guardant Health by 0.4% in the first quarter. First Trust Advisors LP now owns 71,871 shares of the company’s stock worth $5,513,000 after acquiring an additional 264 shares in the last quarter. NEXT Financial Group Inc increased its position in shares of Guardant Health by 20.0% in the second quarter. NEXT Financial Group Inc now owns 1,200 shares of the company’s stock worth $104,000 after acquiring an additional 200 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Guardant Health by 47.9% in the second quarter. Commonwealth Equity Services LLC now owns 5,812 shares of the company’s stock worth $501,000 after acquiring an additional 1,883 shares in the last quarter. Finally, AE Wealth Management LLC purchased a new position in shares of Guardant Health in the second quarter worth approximately $426,000. Institutional investors and hedge funds own 78.19% of the company’s stock.
Guardant Health stock opened at $77.67 on Monday. The firm’s 50 day simple moving average is $71.34 and its 200-day simple moving average is $81.32. The company has a market cap of $7.29 billion, a P/E ratio of -27.74 and a beta of 0.22. Guardant Health Inc has a fifty-two week low of $32.33 and a fifty-two week high of $112.21.
Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.25. Guardant Health had a negative net margin of 40.99% and a negative return on equity of 11.70%. The firm had revenue of $60.85 million for the quarter, compared to the consensus estimate of $45.40 million. During the same period in the previous year, the firm posted ($1.94) earnings per share. The firm’s revenue was up 180.4% on a year-over-year basis. As a group, research analysts predict that Guardant Health Inc will post -0.88 earnings per share for the current fiscal year.
Several research analysts have recently weighed in on GH shares. Canaccord Genuity reissued a “buy” rating and issued a $125.00 target price on shares of Guardant Health in a research report on Friday, November 8th. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. William Blair reissued an “outperform” rating on shares of Guardant Health in a research report on Friday, November 8th. Zacks Investment Research raised shares of Guardant Health from a “hold” rating to a “strong-buy” rating and set a $84.00 target price on the stock in a research report on Tuesday, November 12th. Finally, ValuEngine raised shares of Guardant Health from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Guardant Health currently has a consensus rating of “Buy” and a consensus target price of $107.60.
In related news, VP Timothy P. Eckersley sold 2,364 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.24, for a total transaction of $279,519.36. Also, CFO Derek A. Bertocci sold 25,481 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $79.58, for a total transaction of $2,027,777.98. Following the transaction, the chief financial officer now directly owns 99,684 shares in the company, valued at $7,932,852.72. The disclosure for this sale can be found here. Insiders have sold 5,027,544 shares of company stock worth $387,146,794 over the last ninety days. 13.00% of the stock is currently owned by insiders.
Guardant Health Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Story: How interest rates affect municipal bond prices
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health Inc (NASDAQ:GH).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.